Table 3 Characteristics of patients and survival analysis (by grade of DMVD)
Characteristic | Uniform distribution (DMVD < 10) (n = 187) | Uneven distribution (DMVD > 10) (68) | Statistics | P |
|---|---|---|---|---|
Age (years) | 51.86 ± 9.55 | 52.04 ± 9.84 | -0.138 | 0.890 |
Menopause | Â | Â | 0.389 | 0.572 |
Postmenopausal | 88 | 35 | Â | Â |
Premenopausal | 99 | 33 | Â | Â |
Family history | Â | Â | 0.012 | 1.000 |
No | 174 | 63 | Â | Â |
Yes | 13 | 5 | Â | Â |
Diameter | 2.21 ± 0.95 | 2.67 ± 1.31 | -3.061 | 0.002 |
Quadrant | Â | Â | 5.680 | 0.224 |
Areolar | 3 | 2 | Â | Â |
Inner upper | 39 | 6 | Â | Â |
Inner lower | 17 | 8 | Â | Â |
Outer lower | 32 | 11 | Â | Â |
Outer upper | 96 | 41 | Â | Â |
Patterns of enhancement | Â | Â | 179.854 | 0.000 |
Homogeneous | 77(41.2%) | 5(7.4%) | Â | Â |
Heterogeneous | 110(58.8%) | 11(16.2%) | Â | Â |
Peripheral | 0(0%) | 52(76.5%) | Â | Â |
Difference of MVD (Edge - Center) | 1.29 ± 5.03 | 15.60 ± 4.27 | -20.873 | 0.000 |
Histological grade | Â | Â | 2.105 | 0.349 |
I | 50 | 13 | Â | Â |
II | 120 | 46 | Â | Â |
III | 17 | 9 | Â | Â |
Cancer thrombosis | Â | Â | 1.891 | 0.204 |
Negative | 140 | 45 | Â | Â |
Positive | 47 | 23 | Â | Â |
Nodal metastasis | Â | Â | 0.174 | 0.777 |
Negative | 88 | 30 | Â | Â |
Positive | 99 | 38 | Â | Â |
Number of metastatic nodes | 2.91 ± 5.97 | 6.21 ± 9.42 | -3.302 | 0.001 |
Clinical stage | Â | Â | 18.458 | 0.002 |
I | 46(24.6%) | 13(19.1%) | Â | Â |
IIA | 60(32.1%) | 16(23.5%) | Â | Â |
IIB | 64(34.2%) | 20(29.4%) | Â | Â |
IIIA | 11(5.9%) | 7(10.3%) | Â | Â |
IIIB | 2(1.1%) | 5(7.4%) | Â | Â |
IIIC | 4(2.1%) | 7(10.3%) | Â | Â |
IV | 0(0%) | 0(0%) | Â | Â |
ER | Â | Â | 18.731 | 0.000 |
Negative | 57(30.5%) | 41(60.3%) | Â | Â |
Positive | 130(69.5%) | 27(39.7%) | Â | Â |
PgR | Â | Â | 26.314 | 0.000 |
Negative | 48(25.7%) | 41(60.3%) | Â | Â |
Positive | 139(74.3%) | 27(39.7%) | Â | Â |
HER2 | Â | Â | 9.786 | 0.003 |
Negative | 167(89.3%) | 50(73.5%) | Â | Â |
Positive | 20(10.7%) | 18(26.5%) | Â | Â |
Ki67 | Â | Â | 10.827 | 0.001 |
Negative (<14%) | 120(64.2%) | 28(41.2%) | Â | Â |
Positive (>14%) | 67(35.8%) | 40(58.8%) | Â | Â |
P53 (%) | 32.08 ± 31.58 | 29.90 ± 33.94 | 0.479 | 0.633 |
Clinicopathological subtypes | Â | Â | 42.300 | 0.000 |
Luminal A | 102(54.5%) | 17(25.0%) | Â | Â |
Luminal B (Ki67+) | 44(23.5%) | 8(11.8%) | Â | Â |
Luminal B (HER2+) | 14(7.5%) | 8(11.8%) | Â | Â |
HER2 overexpression | 6(3.2%) | 10(14.7%) | Â | Â |
TNBC | 21(11.2%) | 25(36.8%) | Â | Â |
Operation | Â | Â | 0.819 | 0.485 |
Mastectomy | 166 | 63 | Â | Â |
Tumorectomy | 21 | 5 | Â | Â |
Chemotherapy program | Â | Â | 17.357 | 0.004 |
Not performed | 0(0%) | 2(2.9%) | Â | Â |
CMF | 2(1.1%) | 0(0%) | Â | Â |
CAF or AC | 60(32.1%) | 12(17.6%) | Â | Â |
CEF or EC | 43(23.0%) | 19(27.9%) | Â | Â |
T or TC or TP | 59(31.6%) | 17(25.0%) | Â | Â |
TAC or A-T | 23(12.3%) | 18(26.5%) | Â | Â |
Radiotherapy | Â | Â | 2.012 | 0.160 |
Not performed | 104 | 31 | Â | Â |
Performed | 83 | 37 | Â | Â |
Endocrine therapy | Â | Â | 38.443 | 0.000 |
Not performed | 27(14.4%) | 35(51.5%) | Â | Â |
TAM | 99(52.9%) | 20(29.4%) | Â | Â |
LHRH | 13(7.0%) | 5(7.4%) | Â | Â |
AI | 48(25.7%) | 8(11.8%) | Â | Â |
Targeted therapy | Â | Â | 0.116 | 1.000 |
Not performed | 183 | 67 | Â | Â |
Performed | 4 | 1 | Â | Â |
Overall survival | 99.5% | 85.3% | 24.308 | 0.000 |
Event | 1 | 10 | Â | Â |
Deaths | 1 | 9 | Â | Â |
Lost to Follow-up | 0 | 1 | Â | Â |
Median survival time | 54.0 | 54.0 | 14.885 | 0.000 |
Disease-free survival | 99.5% | 67.6% | 62.030 | 0.000 |
Event | 1 | 22 | Â | Â |
Local recurrence | 0 | 1 | Â | Â |
Contralateral breast cancer | 0 | 4 | Â | Â |
Lung metastasis | 0 | 2 | Â | Â |
Hepatic metastasis | 0 | 5 | Â | Â |
Brain metastasis | 0 | 3 | Â | Â |
Multi-organ | 1 | 6 | Â | Â |
Lost to Follow-up | 0 | 1 | Â | Â |
Disease-free survival | 54.0 | 31.9 | 47.546 | 0.000 |
Follow-up time | Â | Â | 0.384 | 0.701 |
Median | 23.0 | 22.0 | Â | Â |
Range | 12-58 | 12-59 | Â | Â |